摩通:升中芯(0981.HK)評級至“中性” 目標價上調至23港元
摩根大通發表報吿表示,認為中芯國際(0981.HK)可受惠成熟製程需求強勁,收入及毛利均有上行,故帶動產能利用率強勁增長,該行將公司每股盈測上調,並將評級由減持升至中性,目標價由20港元升至23港元,此相當於未來12個月預測市賬率1.4倍。
摩根大通指出,受惠特別是內地半導體需求強勁,中芯估計上半年收入將按年升30%,高於市場原先估計的15%,相信是由於成熟製程產能擴張,加上產能利用率較高及平均銷售單價提升,估計晶圓整體平均銷售單價次季續升7-9%,主要由於價格上升及產品組合改善等。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.